|
US4866034A
(en)
*
|
1982-05-26 |
1989-09-12 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
|
CA1225592A
(en)
*
|
1983-08-26 |
1987-08-18 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
|
US4987237A
(en)
*
|
1983-08-26 |
1991-01-22 |
Ribi Immunochem Research, Inc. |
Derivatives of monophosphoryl lipid A
|
|
US4663306A
(en)
*
|
1983-09-23 |
1987-05-05 |
Ribi Immunochem Research, Inc. |
Pyridine-soluble extract-refined detoxified endotoxin composition and use
|
|
JPS61151157A
(ja)
*
|
1984-12-25 |
1986-07-09 |
Seiko Instr & Electronics Ltd |
タンパク質を加水分解する方法
|
|
US4806352A
(en)
*
|
1986-04-15 |
1989-02-21 |
Ribi Immunochem Research Inc. |
Immunological lipid emulsion adjuvant
|
|
US4877611A
(en)
*
|
1986-04-15 |
1989-10-31 |
Ribi Immunochem Research Inc. |
Vaccine containing tumor antigens and adjuvants
|
|
US4929604A
(en)
*
|
1986-05-28 |
1990-05-29 |
Board Of Regents, The University Of Texas System |
Lipopolysaccharides of reduced toxicity and the production thereof
|
|
US4845036A
(en)
*
|
1987-02-03 |
1989-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for isolation of the B oligomer of pertussis toxin
|
|
JPH01141942U
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
1988-03-24 |
1989-09-28 |
|
|
|
JPH01180041U
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
1988-06-09 |
1989-12-25 |
|
|
|
US5416070A
(en)
*
|
1988-07-08 |
1995-05-16 |
Immunotherapeutics, Inc. |
Composition for macrophage activation
|
|
US4950645A
(en)
*
|
1988-07-08 |
1990-08-21 |
Immunotherapeutics, Inc. |
Composition for macrophage activation
|
|
WO1990003183A1
(en)
*
|
1988-09-23 |
1990-04-05 |
University Of Southern California |
Immunotherapy vaccine for melanoma tumors
|
|
JPH02124341U
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
*
|
1989-03-24 |
1990-10-12 |
|
|
|
US5286718A
(en)
*
|
1991-12-31 |
1994-02-15 |
Ribi Immunochem Research, Inc. |
Method and composition for ameliorating tissue damage due to ischemia and reperfusion
|
|
US6218166B1
(en)
|
1994-12-09 |
2001-04-17 |
John Wayne Cancer Institute |
Adjuvant incorporation into antigen carrying cells: compositions and methods
|
|
US6190657B1
(en)
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US5762943A
(en)
*
|
1996-05-14 |
1998-06-09 |
Ribi Immunochem Research, Inc. |
Methods of treating type I hypersensitivity using monophosphoryl lipid A
|
|
US6491919B2
(en)
*
|
1997-04-01 |
2002-12-10 |
Corixa Corporation |
Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
|
|
EP1012232B1
(en)
|
1997-09-10 |
2009-10-28 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
CN101219217A
(zh)
*
|
1998-05-07 |
2008-07-16 |
科里克萨有限公司 |
佐剂组合物及其使用方法
|
|
DK2272859T3
(en)
|
1998-08-07 |
2015-01-19 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for their use
|
|
US6013640A
(en)
|
1998-08-21 |
2000-01-11 |
Ribi Immunochem Research, Inc. |
Phosphoglycolipid and methods for its use
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
AU769293B2
(en)
|
1998-12-08 |
2004-01-22 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
|
AU4057300A
(en)
|
1999-03-30 |
2000-10-16 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinacious compounds
|
|
HK1049848A1
(zh)
|
1999-04-02 |
2003-05-30 |
科里克萨有限公司 |
用於治療和診斷肺癌的化合物和方法
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
|
TR200103018T2
(tr)
|
1999-04-19 |
2002-02-21 |
Beecham Biologicals S.A. Smithkline |
İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
|
|
US20020022032A1
(en)
*
|
1999-04-23 |
2002-02-21 |
Curry Patrick Mark |
Immuno-adjuvant PDT treatment of metastatic tumors
|
|
GB9919468D0
(en)
|
1999-08-17 |
1999-10-20 |
Smithkline Beecham Biolog |
Vaccine
|
|
US6962696B1
(en)
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
|
AU779978B2
(en)
*
|
1999-10-07 |
2005-02-24 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
EP1964573B1
(en)
|
1999-10-22 |
2014-11-26 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
GB0000891D0
(en)
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
|
CN1254541C
(zh)
|
2000-02-23 |
2006-05-03 |
史密丝克莱恩比彻姆生物有限公司 |
新化合物
|
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US6699846B2
(en)
|
2000-03-17 |
2004-03-02 |
Corixa Corporation |
Mono- and disaccharides for the treatment of nitric oxide related disorders
|
|
DE60133190T2
(de)
|
2000-04-21 |
2009-04-02 |
CORIXA CORP., Wilmington |
Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
|
|
EP1282702B1
(en)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
|
AU2001269695B2
(en)
|
2000-05-19 |
2007-02-15 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
|
|
US20030139356A1
(en)
*
|
2001-05-18 |
2003-07-24 |
Persing David H. |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
|
|
DK1542732T3
(da)
|
2000-06-20 |
2009-12-14 |
Corixa Corp |
Fusionsproteiner af Mycobacterium tuberculosis
|
|
AR029540A1
(es)
|
2000-06-28 |
2003-07-02 |
Corixa Corp |
COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
|
|
DE60131670T2
(de)
|
2000-10-18 |
2008-10-30 |
Glaxosmithkline Biologicals S.A. |
Impfstoffe gegen Krebskrankheiten
|
|
DE60239594D1
(de)
|
2001-02-23 |
2011-05-12 |
Glaxosmithkline Biolog Sa |
Influenza vakzinzusammensetzungen zur intradermaler verabreichung
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
|
EP2241309A3
(en)
|
2001-07-10 |
2012-12-26 |
Corixa Corporation |
Methods for encapsulation of proteins and adjuants in microspheres
|
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
|
IL160809A0
(en)
|
2001-09-20 |
2004-08-31 |
Glaxo Group Ltd |
HIV-gag CODON-OPTIMISED DNA VACCINES
|
|
ES2405405T3
(es)
|
2001-12-17 |
2013-05-31 |
Corixa Corporation |
Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
|
AU2003213640A1
(en)
*
|
2002-02-28 |
2003-09-16 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
|
AU2003251824B8
(en)
|
2002-07-08 |
2010-08-05 |
Corixa Corporation |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
|
|
SI2269656T1
(sl)
|
2002-07-15 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
|
|
ATE494907T1
(de)
|
2002-07-18 |
2011-01-15 |
Univ Washington |
Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
|
|
EP1569515A4
(en)
|
2002-10-23 |
2006-04-26 |
Glaxosmithkline Biolog Sa |
MALARIA vaccine method
|
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
HRP20130407T1
(en)
|
2003-09-02 |
2013-06-30 |
Glaxosmithkline Biologicals S.A. |
Rotavirus vaccine
|
|
EP2816351A3
(en)
*
|
2004-01-27 |
2015-03-25 |
Compugen Ltd. |
Methods and systems for annotating biomolecular sequences
|
|
ES2422171T3
(es)
*
|
2004-02-11 |
2013-09-09 |
Ligocyte Pharmaceuticals Inc |
Antígenos de carbunco y procedimientos de uso
|
|
EP1766096B1
(en)
|
2004-05-25 |
2013-01-02 |
Oregon Health and Science University |
Hiv vaccination usingand hcmv-based vaccine vectors
|
|
WO2005117958A1
(en)
|
2004-05-28 |
2005-12-15 |
Glaxosmithkline Biologicals S.A. |
Vaccine compositions comprising virosomes and a saponin adjuvant
|
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EP3312272B1
(en)
|
2004-10-08 |
2019-08-28 |
The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services |
Modulation of replicative fitness by using less frequently used synonymous codons
|
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EP1863529A1
(en)
*
|
2005-03-23 |
2007-12-12 |
GlaxoSmithKline Biologicals S.A. |
Novel composition
|
|
EA014527B1
(ru)
|
2005-03-31 |
2010-12-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцины против хламидиоза
|
|
EA012576B1
(ru)
|
2005-04-29 |
2009-10-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Новый способ предупреждения или лечения инфекции, вызываемой m.tuberculosis
|
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
|
US7622128B2
(en)
*
|
2005-12-13 |
2009-11-24 |
University Of Washington |
Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
|
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
|
US8128921B2
(en)
*
|
2006-07-11 |
2012-03-06 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
|
MX2009000660A
(es)
|
2006-07-17 |
2009-04-08 |
Glaxosmithkline Biolog Sa |
Vacuna de influenza.
|
|
US20080124355A1
(en)
|
2006-09-22 |
2008-05-29 |
David Gordon Bermudes |
Live bacterial vaccines for viral infection prophylaxis or treatment
|
|
HUE037808T2
(hu)
|
2006-09-26 |
2018-09-28 |
Infectious Disease Res Inst |
Szintetikus adalékanyagot tartalmazó vakcina kompozíció
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
WO2008059307A2
(en)
*
|
2006-11-16 |
2008-05-22 |
Om Pharma |
Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
|
|
CN101687027B
(zh)
|
2007-04-04 |
2015-01-28 |
传染性疾病研究院 |
包含结核分枝杆菌多肽及其融合的免疫原性组合物
|
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
|
EP3061462B1
(en)
|
2007-07-02 |
2019-02-27 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
US8747861B2
(en)
*
|
2007-08-02 |
2014-06-10 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
|
ES2658347T3
(es)
|
2007-08-13 |
2018-03-09 |
Glaxosmithkline Biologicals Sa |
Vacunas
|
|
US20090215908A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Toll like receptor (tlr) signaling antagonist
|
|
US20090215710A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Carbohydrate based toll-like receptor (tlr) antagonists
|
|
US8236318B2
(en)
|
2007-11-07 |
2012-08-07 |
Celldex Therapeutics Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
|
US8637053B2
(en)
|
2007-12-03 |
2014-01-28 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
|
JP5711972B2
(ja)
|
2007-12-24 |
2015-05-07 |
アイディー バイオメディカル コーポレイション オブ ケベック |
組換えｒｓｖ抗原
|
|
WO2009095925A2
(en)
*
|
2008-01-31 |
2009-08-06 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
AU2009248810B2
(en)
|
2008-05-23 |
2013-12-05 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
|
CN102123724B
(zh)
|
2008-06-19 |
2018-05-01 |
变异生技公司 |
治疗流行性感冒的组合物和方法
|
|
BRPI0915960A2
(pt)
*
|
2008-07-18 |
2019-09-24 |
Id Biomedical Corp |
antígenos de polipeptídeos do vírus sincicial respiratório qimérico
|
|
WO2010036945A2
(en)
|
2008-09-26 |
2010-04-01 |
The Regents Of The University Of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
|
CN102239253A
(zh)
|
2008-12-03 |
2011-11-09 |
普罗蒂亚维仕尼科技有限公司 |
谷氨酰tRNA合成酶（GtS）片段
|
|
US8241623B1
(en)
|
2009-02-09 |
2012-08-14 |
David Bermudes |
Protease sensitivity expression system
|
|
CN102395600B
(zh)
|
2009-02-17 |
2015-03-25 |
葛兰素史密斯克莱生物公司 |
含有无铝佐剂的灭活的登革热病毒疫苗
|
|
US20110097418A1
(en)
*
|
2009-05-29 |
2011-04-28 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating influenza
|
|
CA2764374C
(en)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
|
CA2765511C
(en)
|
2009-06-16 |
2015-05-12 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
|
SG176807A1
(en)
|
2009-06-24 |
2012-01-30 |
Id Biomedical Corp Quebec |
Vaccine
|
|
US9492531B2
(en)
|
2009-06-24 |
2016-11-15 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV vaccines
|
|
US9907746B2
(en)
|
2009-07-06 |
2018-03-06 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
BR112012000826B1
(pt)
|
2009-07-06 |
2022-07-26 |
Variation Biotechnologies Inc |
Método para a preparação de vesículas
|
|
ES2563730T3
(es)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
|
|
EP2477652B1
(en)
|
2009-09-16 |
2015-04-15 |
Vaxart, Inc. |
Immunization strategy to prevent h1n1 infection
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
|
US8524220B1
(en)
|
2010-02-09 |
2013-09-03 |
David Gordon Bermudes |
Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
|
|
US8771669B1
(en)
|
2010-02-09 |
2014-07-08 |
David Gordon Bermudes |
Immunization and/or treatment of parasites and infectious agents by live bacteria
|
|
NZ623807A
(en)
|
2010-04-13 |
2016-03-31 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
|
MX354752B
(es)
|
2010-09-27 |
2018-03-20 |
Janssen Vaccines & Prevention Bv |
Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
|
|
BR112013008624B1
(pt)
|
2010-10-15 |
2022-07-26 |
Glaxosmithkline Biologicals S.A. |
Polipeptídeo gb de citomegalovírus (cmv), preparação, composição imunogênica, polinucleotídeo, vetor recombinante, e, microrganismo transgênico
|
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
|
EA201390676A1
(ru)
|
2010-11-08 |
2013-11-29 |
Инфекшес Дизиз Рисерч Инститьют |
Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
|
|
KR20190022897A
(ko)
|
2010-12-14 |
2019-03-06 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
미코박테리움 항원성 조성물
|
|
BR112013017939B1
(pt)
|
2011-01-13 |
2022-11-16 |
Variation Biotechnologies Inc |
Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
|
|
EP2663288B1
(en)
|
2011-01-13 |
2022-12-21 |
Variation Biotechnologies Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
|
CN103517713A
(zh)
|
2011-02-22 |
2014-01-15 |
彼昂德瓦克斯医药有限公司 |
在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
|
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
|
DK3275892T3
(da)
|
2011-05-13 |
2020-04-06 |
Glaxosmithkline Biologicals Sa |
Præfusions-rsv-f-antigener
|
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
HRP20190917T1
(hr)
|
2011-09-16 |
2019-07-26 |
Ucb Biopharma Sprl |
NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE
|
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
|
GB201119999D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
CN104302323A
(zh)
|
2012-01-12 |
2015-01-21 |
变异生物技术公司 |
用于治疗病毒感染的组合物和方法
|
|
AU2013213345A1
(en)
|
2012-01-27 |
2014-08-28 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
|
EP3563834A1
(en)
|
2012-02-07 |
2019-11-06 |
Infectious Disease Research Institute |
Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
|
|
JP2015514696A
(ja)
|
2012-03-18 |
2015-05-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ヒト・パピローマウイルスに対するワクチン接種方法
|
|
EP3492095A1
(en)
|
2012-04-01 |
2019-06-05 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
|
WO2014042780A1
(en)
|
2012-08-03 |
2014-03-20 |
Infectious Disease Research Institute |
Compositions and methods for treating an active mycobacterium tuberculosis infection
|
|
WO2014024026A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
|
AU2013354186A1
(en)
|
2012-12-05 |
2014-06-12 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
|
JP6125041B2
(ja)
|
2013-01-02 |
2017-05-10 |
デコイ バイオシステムズ インコーポレイテッドＤｅｃｏｙ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． |
細菌を用いた癌治療用組成物およびその製造のための菌の使用
|
|
CA2900008A1
(en)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
|
US9593339B1
(en)
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
|
PT2970398T
(pt)
|
2013-03-13 |
2024-06-07 |
The Us Secretary Department Ofhealth And Human Servic |
Proteínas f de pré-fusão do vsr e sua utilização
|
|
US10058603B2
(en)
|
2013-03-15 |
2018-08-28 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
US9909114B2
(en)
|
2013-03-28 |
2018-03-06 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
EP3632458B1
(en)
|
2013-07-26 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
|
WO2015018806A1
(en)
|
2013-08-05 |
2015-02-12 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
|
KR102399854B1
(ko)
|
2013-09-19 |
2022-05-19 |
노바백스, 인코포레이티드 |
면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
|
|
CA2928700C
(en)
|
2013-11-01 |
2019-01-15 |
University Of Oslo |
Albumin variants and uses thereof
|
|
US11452767B2
(en)
|
2013-11-15 |
2022-09-27 |
Oslo Universitetssykehus Hf |
CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
KR102850294B1
(ko)
|
2013-12-31 |
2025-08-26 |
액세스 투 어드밴스드 헬스 인스티튜트 |
단일 바이알 백신 제형
|
|
AU2015218769B2
(en)
|
2014-02-20 |
2020-09-17 |
Vaxart, Inc. |
Formulations for small intestinal delivery
|
|
JP6550072B2
(ja)
|
2014-04-03 |
2019-07-24 |
バイオンドバックス ファーマシューティカルズ リミテッド |
多量体マルチエピトープインフルエンザポリペプチドの組成物及びそれらの生成
|
|
US10420833B2
(en)
|
2014-05-19 |
2019-09-24 |
Board Of Regents, The University Of Texas System |
Combinatorial platform for the display of surface adjuvants and antigens
|
|
BR112016028816A8
(pt)
|
2014-06-13 |
2021-07-20 |
Glaxosmithkline Biologicals Sa |
combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
|
|
PT3160500T
(pt)
|
2014-06-25 |
2019-11-11 |
Glaxosmithkline Biologicals Sa |
Composição imunogénica de clostridium difficile
|
|
EP3169699A4
(en)
|
2014-07-18 |
2018-06-20 |
The University of Washington |
Cancer vaccine compositions and methods of use thereof
|
|
EP3204039B1
(en)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
|
ES2881346T3
(es)
|
2014-12-19 |
2021-11-29 |
Regenesance B V |
Anticuerpos que se unen a C6 humano y usos de los mismos
|
|
CA2974237C
(en)
|
2015-01-09 |
2021-07-20 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
EP4226937A3
(en)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
WO2016172249A1
(en)
|
2015-04-20 |
2016-10-27 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
|
RU2017140856A
(ru)
|
2015-05-26 |
2019-06-26 |
Огайо Стейт Инновейшн Фаундейшн |
Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
|
|
KR102773575B1
(ko)
|
2015-06-12 |
2025-02-27 |
박사르트, 인크. |
Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
|
|
WO2017062246A1
(en)
|
2015-10-05 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rota virus g9p[6] strain and use as a vaccine
|
|
MX2018010586A
(es)
|
2016-03-02 |
2019-03-28 |
Univ Texas |
Nanovacuna de activacion de "sting" para inmunoterapia.
|
|
CR20180445A
(es)
|
2016-03-14 |
2019-02-08 |
Univ Oslo |
Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn
|
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
|
|
DK3458475T3
(da)
|
2016-05-16 |
2022-09-12 |
Access To Advanced Health Inst |
Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
|
|
KR102483033B1
(ko)
|
2016-05-16 |
2022-12-30 |
액세스 투 어드밴스드 헬스 인스티튜트 |
페길화된 리포솜 및 이의 용도
|
|
CN109310748A
(zh)
|
2016-05-21 |
2019-02-05 |
传染病研究所 |
用于治疗继发性结核和非结核分枝杆菌感染的组合物和方法
|
|
KR20200138418A
(ko)
|
2016-05-27 |
2020-12-09 |
이투빅스 코포레이션 |
네오에피토프 백신 조성물 및 이의 사용 방법
|
|
KR20250008135A
(ko)
|
2016-06-01 |
2025-01-14 |
액세스 투 어드밴스드 헬스 인스티튜트 |
사이징제를 함유하는 나노명반 입자
|
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
|
EP3485002A4
(en)
|
2016-07-13 |
2020-07-29 |
Ohio State Innovation Foundation |
PLATFORMS AND METHODS FOR THE OPTIMIZATION OF ANTIGEN PRESENTATION BY THE HOST, AND ANTI-TUMOR AND ANTI-INFECTIOUS IMMUNITY OF THE HOST
|
|
US11498956B2
(en)
|
2016-08-23 |
2022-11-15 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
|
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
|
BR112019004913B1
(pt)
|
2016-09-16 |
2022-07-12 |
Infectious Disease Research Institute |
Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
BR112019011286A2
(pt)
|
2016-12-07 |
2019-10-15 |
Glaxosmithkline Biologicals Sa |
métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
EP3554538A2
(en)
|
2016-12-16 |
2019-10-23 |
Institute for Research in Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
|
UA129243C2
(uk)
|
2017-04-19 |
2025-02-26 |
Інстітьют Фо Рісьорч Ін Біомедцін |
Антитіло, що зв'язується зі спорозоїтами p. falciparum
|
|
CN110621339A
(zh)
|
2017-04-28 |
2019-12-27 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗接种
|
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
|
IE20190084A3
(en)
|
2017-05-30 |
2023-07-19 |
Glaxosmithkline Biologicals Sa |
Novel methods for manufacturing an adjuvant
|
|
KR20240096685A
(ko)
|
2017-06-15 |
2024-06-26 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
|
EP3638301A1
(en)
|
2017-06-16 |
2020-04-22 |
GlaxoSmithKline Biologicals S.A. |
Method of treatment
|
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
|
US12268736B2
(en)
|
2017-09-07 |
2025-04-08 |
University Of Oslo |
Vaccine molecules
|
|
EP3678699A1
(en)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Vaccine molecules
|
|
CN111315406A
(zh)
|
2017-09-08 |
2020-06-19 |
传染病研究所 |
包括皂苷的脂质体调配物及其使用方法
|
|
EP3717001A1
(en)
|
2017-12-01 |
2020-10-07 |
GlaxoSmithKline Biologicals S.A. |
Saponin purification
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
|
EP3743102A1
(en)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
TW202003023A
(zh)
|
2018-03-12 |
2020-01-16 |
美商詹森藥物公司 |
針對尿路感染之疫苗
|
|
JP7466459B2
(ja)
|
2018-04-17 |
2024-04-12 |
セルデックス セラピューティクス インコーポレイテッド |
抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
|
|
EP3807298A1
(en)
|
2018-06-12 |
2021-04-21 |
GlaxoSmithKline Biologicals S.A. |
Adenovirus polynucleotides and polypeptides
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
MX2021001129A
(es)
|
2018-07-31 |
2021-07-02 |
Glaxosmithkline Biologicals Sa |
Metodo de purificacion de antigenos.
|
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
|
US12239699B2
(en)
|
2018-09-11 |
2025-03-04 |
Shanghai Public Health Clinical Center |
Immunogen for broad-spectrum influenza vaccine and application thereof
|
|
US20220184158A1
(en)
|
2018-12-21 |
2022-06-16 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
|
US20220339281A1
(en)
|
2019-03-05 |
2022-10-27 |
GalxoSmithKline Biologicals SA |
Hepatitis b immunisation regimen and compositions
|
|
AU2020283768A1
(en)
|
2019-05-25 |
2021-12-23 |
Access To Advanced Health Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
|
CA3142300A1
(en)
|
2019-06-05 |
2020-12-10 |
Glaxosmithkline Biologicals Sa |
Saponin purification
|
|
AU2020318680B2
(en)
|
2019-07-21 |
2025-04-24 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
|
WO2021014385A1
(en)
|
2019-07-24 |
2021-01-28 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
|
EP4028051A1
(en)
|
2019-09-09 |
2022-07-20 |
GlaxoSmithKline Biologicals S.A. |
Immunotherapeutic compositions
|
|
EP4038091A1
(en)
|
2019-10-02 |
2022-08-10 |
Janssen Vaccines & Prevention B.V. |
Staphylococcus peptides and methods of use
|
|
EP4058581A1
(en)
|
2019-11-15 |
2022-09-21 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
|
WO2021122551A1
(en)
|
2019-12-19 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
S. aureus antigens and compositions thereof
|
|
FI4090363T3
(fi)
|
2020-01-16 |
2024-09-25 |
Janssen Pharmaceuticals Inc |
FimH-mutantti, sen koostumuksia ja sen käyttö
|
|
WO2021178637A1
(en)
|
2020-03-05 |
2021-09-10 |
Iowa State University Research Foundation, Inc. |
IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
|
|
JP2023524136A
(ja)
|
2020-05-05 |
2023-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
マイクロ流体混合デバイス及び使用方法
|
|
MX2022015287A
(es)
|
2020-06-01 |
2023-02-22 |
Loop Diagnostics S L |
Metodo y kit para la deteccion temprana de septicemia.
|
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
EP4188427A1
(en)
|
2020-08-03 |
2023-06-07 |
GlaxoSmithKline Biologicals S.A. |
Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
|
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
US20240115688A1
(en)
|
2020-12-02 |
2024-04-11 |
Glaxosmithkline Biologicals Sa |
Novel Antigens
|
|
WO2022122830A2
(en)
|
2020-12-09 |
2022-06-16 |
Glaxosmithkline Biologicals Sa |
Saponins
|
|
MX2023007596A
(es)
|
2020-12-24 |
2024-02-23 |
Plant Bioscience Ltd |
Metodos y enzimas para la producción de derivados del ácido quillaico.
|
|
TW202241929A
(zh)
|
2021-01-12 |
2022-11-01 |
美商詹森藥物公司 |
ＦｉｍＨ突變體、其組成物及其用途
|
|
EP4032547A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce derived fragements for the treatment of hsv
|
|
JP2024506364A
(ja)
|
2021-02-11 |
2024-02-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｈｐｖワクチンの製造
|
|
CA3215752A1
(en)
|
2021-04-01 |
2022-10-06 |
Janssen Pharmaceuticals, Inc. |
Production of e. coli o18 bioconjugates
|
|
EP4320159A1
(en)
|
2021-04-09 |
2024-02-14 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
|
WO2023144665A1
(en)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
|
EP4499817A1
(en)
|
2022-03-25 |
2025-02-05 |
Plant Bioscience Limited |
Biosynthesis
|
|
WO2023242187A1
(en)
|
2022-06-15 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Enzymatic modification of saponins
|
|
GB202209588D0
(en)
|
2022-06-29 |
2022-08-10 |
Plant Bioscience Ltd |
Methods and compositions
|
|
AU2023336224A1
(en)
|
2022-09-09 |
2025-03-27 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
|
CN120456919A
(zh)
|
2022-12-19 |
2025-08-08 |
葛兰素史克生物有限公司 |
乙型肝炎组合物
|
|
WO2024160901A1
(en)
|
2023-02-02 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
WO2024186635A2
(en)
|
2023-03-03 |
2024-09-12 |
Celldex Therapeutics, Inc. |
Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
|
|
WO2024241172A2
(en)
|
2023-05-19 |
2024-11-28 |
Glaxosmithkline Biologicals Sa |
Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
|